Can Semaglutide Cause Heart Problems — or Does It Protect Them?

The misconception worth correcting first: semaglutide does not damage the heart

When people search whether semaglutide can cause heart problems, the underlying worry is usually: could this medicine harm my heart? The clinical record does not support that concern for the broad population who take it. The SELECT trial (a large cardiovascular outcome study involving adults with established cardiovascular disease, overweight or obesity, but without diabetes) found that semaglutide 2.4mg (Wegovy) reduced the combined risk of heart attack, stroke and cardiovascular death by around 20% compared with placebo over roughly three years. That result led directly to the MHRA granting Wegovy a UK licence extension beyond weight management to cover reduction of major cardiovascular events in eligible adults.

This does not mean semaglutide is a heart medicine for everyone, or that it overrides the need for proper cardiac care. It means the evidence, on balance, points away from harm and towards benefit for people who are appropriate candidates. More detail on semaglutide's relationship with cardiovascular health is worth reading if your primary concern is cardiac rather than weight-related.

The NHS summarises the cardiovascular profile of semaglutide medicines on its dedicated tirzepatide and semaglutide medicines pages, which are updated as new safety information emerges.

What semaglutide can do to heart rate, and why it usually settles

Here is where the answer needs a little more nuance. A modest increase in resting heart rate (typically around two to three beats per minute on average) is a recognised effect of GLP-1 medicines including semaglutide. Some people notice this more acutely in the first few weeks, particularly around dose increases. For most, it is clinically insignificant and not something that warrants stopping treatment.

A smaller number of people report more noticeable palpitations, especially early on. This is worth flagging to your prescriber if it feels uncomfortable or persists, but it is distinct from the kind of structural cardiac harm the search query often implies. Palpitations on Wegovy are a topic we've covered separately for people who want to understand exactly what's happening and when to act.

If you are already taking medication that affects heart rate (beta-blockers, for example) your prescriber will factor that in. Pull your weekly Wegovy pen out of the fridge door the same evening every week; a consistent routine helps you notice if anything feels different and gives you a clear reference point when talking to your clinical team.

For a closer look at how semaglutide interacts with heart rate specifically, this page on semaglutide and heart rate covers the mechanism and the trial data.

When pre-existing heart conditions change the picture

Most of the concern about semaglutide and the heart relates not to otherwise healthy adults, but to people who already have significant cardiac conditions. The evidence here is broadly reassuring (SELECT deliberately enrolled adults with established cardiovascular disease) but there are situations where extra caution applies.

If you have heart failure, certain arrhythmias, or are on a complex cardiac medication regimen, a prescriber needs to review the specifics before semaglutide is appropriate. This is not a blanket exclusion; it is a clinical judgement call that depends on your particular condition, its severity and your other medications. The guidance on taking semaglutide with existing heart problems goes into that clinical reasoning in detail.

Separately, kidney function is worth mentioning in the cardiac context: the two systems are linked, and conditions like chronic kidney disease often co-exist with cardiovascular disease. Wegovy and kidney health explains what the evidence shows there.

The MHRA's Drug Safety Update series carries the most current regulatory communications on GLP-1 medicines, including any emerging cardiac signals. Readers with specific concerns about drug interactions or contraindications should also speak directly to a prescriber before making any decisions about treatment, or about stopping a treatment already in progress.

How a prescriber assesses this before treatment starts

At nume, every consultation is read by a GPhC-registered Independent Prescriber, a real clinician, not an automated screening tool. Cardiac history, current medications and any relevant test results are part of what they consider. If your history includes heart problems, you may be asked for more detail; the prescriber decides whether semaglutide is appropriate and at what starting point.

Semaglutide (Wegovy) is licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Being within the licensed BMI range does not automatically mean the medicine is suitable, the prescriber's job is to look at the whole picture. You can read more about Wegovy's UK licence and how it works or explore our weight-loss treatment options if you are still deciding which approach fits your situation.

For anyone thinking about the cost side of things alongside the clinical questions, Wegovy pricing in the UK explains what a legitimate private prescription actually covers. When you're ready to talk through your own history with a prescriber, starting a free consultation is the place to begin.